Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2018.10.11
Active substance: sildenafil
The STRIDER clinical trial, which was studying sildenafil for treating intrauterine growth restriction (IUGR), has been prematurely discontinued due to a higher incidence of persistent pulmonary hypertension of the newborn (PPHN) and overall neonatal death in the sildenafil arm of the study. Sildenafil is not approved for IUGR and should not be used for treating IUGR. Sildenafil should only be used in accordance with the current product information.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN